Il 11 luglio 2024, l’UniversitΓ degli Studi di Catania (UNICT) ha ospitato l’evento π ππ’ππππ«π’ πππ² ππππ π, una giornata dedicata all’innovazione e alla ricerca scientifica. Siamo lieti di annunciare che Combine Group ha avuto l’opportunitΓ di partecipare a questo prestigioso evento, dimostrando il valore e l’impatto del nostro lavoro. Un Palcoscenico per l’Innovazione La…
Read more
Drug development, testing, and approval are intricate processes that typically take 10 to 15 years and cost millions of euros. Most of this time and money are invested in clinical trials, which are essential for proving the drug’s safety and effectiveness. But have you ever wondered if this process could be made faster, cheaper, and…
Read more
3 maggio 2024 π Conference Center Four Points by Sheraton Catania Hotel Incontro scientifico “π·ππππππππππ π ππππ π
ππ ππππππ ππππ’πππ π
πππ’ππππππππππππ πππππππππππ” Durante l’incontro scientifico che si Γ¨ tenuto oggi al Conference Center Four Points by Sheraton Catania Hotel, il Prof. Francesco Pappalardo ha presentato un’intervento di grande interesse dal titolo “ππͺππ£ππ€ π π’π€πππ‘π‘π ππ€π’π₯πͺπ©ππ―ππ€π£ππ‘π…
Read more
Don’t miss out on Professor Francesco Pappalardo’s interview discussing the study on the #JollyVaccine!
We’re thrilled to announce that our research team at the University of Catania is on the front page of #UnictMagazine with a groundbreaking new study on the #JollyVaccine! In this pioneering study, we’ve worked tirelessly to develop an innovative solution to address the challenges associated with vaccination, focusing on the concept of a “Jolly Vaccine.”…
Read more
Article: ‘Sviluppare un vaccino influenzale universale simulanndo gli anticorpi’ In the latest edition of #LaSicilia, a groundbreaking study has been highlighted, shedding light on the development of a universal influenza vaccine through the simulation of antibodies. Conducted by the esteemed research team led by Prof. Francesco Pappalardo at the #CombineGroup, this study has immense implications…
Read more
In the ever-evolving landscape of medical research and technology, advancements often go unnoticed until they reach a critical mass of recognition. However, for the Universal Immune System Simulator (UISS), developed by Professor Francesco Pappalardo and his team, that recognition has arrived in a flurry of attention from seven prestigious newspapers. This marks a significant milestone…
Read more
Uniting the In Silico Community: Insights from the Workshop on Regulatory Barriers in Catania In the serene ambiance of the Monastero dei Benedettini in Catania, the annual gathering of the In Silico community took place on March 14-15. The workshop, titled “The Regulatory Barriers to In Silico Trials,” served as a pivotal platform for experts…
Read more
We take immense pride in presenting the application brief for #tuberculosis treatment, “TBValid collection: Tuberculosis data,” utilizing UISS-TB, an in silico trial solution employing agent-based modeling. “The creation of a synthetically generated, fully anonymized data collection from real-world sources is pivotal for advancing in silico trials targeting crucial factors in silico trials of antivancing in…
Read more
The Combine Group is delighted to announce our involvement in yet another project funded under the Horizon Europe Program: Novel Immunotherapies for Tuberculosis and other Mycobacterial Diseases (ITHEMYC) ???? This venture is a significant opportunity to apply innovative solutions in silico modelling to facilitate both in vitro and in vivo preclinical progression and predict the…
Read more